NCT00333177View on ClinicalTrials.gov

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2013

Study Completion Date

January 31, 2013

Conditions
Schizophrenia
Interventions
BEHAVIORAL

Cognitive remediation training (CT)

Cognitive remediation training includes computerized cognitive training plus learning skills group.

BEHAVIORAL

Healthy behavior training (HBT)

Healthy behavior training includes group skills training in nutrition, exercise, and relaxation.

DRUG

Risperidone, administered orally (Oral Ris)

Oral risperidone at dosage judged optimal by treating psychiatrist

DRUG

Risperidone, administered via injection (RLAI)

Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed

Trial Locations (1)

90095

Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

University of California, Los Angeles

OTHER

NCT00333177 - Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia | Biotech Hunter | Biotech Hunter